Evidence map›Paper›PMID 35370379›Full record

ArticleAyu

Efficacy and safety of

Umesh Shukla, Nitin Ujjaliya, Pankaj Gupta, Vivek Khare, Babita Yadav, Amit Kumar Rai, Hetalben Amin, Rakesh Rana, Arunabh Tripathi, Shruti Khanduri and 4 more

Open access · greenAbstract read
In one paragraph

Article in Ayu. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Umesh ShuklaPrincipal & CEO, Pt. Khushilal Sharma Government (Autonomous) Ayurveda College & Institute, Bhopal, Madhya Pradesh, India.
Nitin UjjaliyaDepartment of Dravyaguna, Pt. Khushilal Sharma Government (Autonomous) Ayurveda College & Institute, Bhopal, Madhya Pradesh, India.
Pankaj GuptaDepartment of Rachana Sharira, Pt. Khushilal Sharma Government (Autonomous) Ayurveda College & Institute, Bhopal, Madhya Pradesh, India.
Vivek KhareDepartment of Pathology, Pt. Khushilal Sharma Government (Autonomous) Ayurveda College & Institute, Bhopal, Madhya Pradesh, India.
Babita YadavDepartment of Ayurveda, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Amit Kumar RaiDepartment of Ayurveda, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Hetalben AminDepartment of Ayurveda, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Rakesh RanaDepartment of Biostatistics, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Arunabh TripathiDepartment of Biostatistics, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Shruti KhanduriDepartment of Ayurveda, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Bhagwan Sahay SharmaDepartment of Ayurveda, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Bhogavalli ChandrasekhararaoDepartment of Ayurveda, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Narayanam SrikanthDirector General (Additional Charge), Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Kartar Singh DhimanFormer Director General, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India.
Central Council for Research in Ayurvedic Science · INGovernment of India · INMinistry of AYUSH · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Currently, there is no approved treatment for the management of coronavirus disease (COVID-19). Drug repurposing of existing medications could be a possible way to find out a novel therapeutic entity to combat the COVID-19. Aim: To determine the clinical efficacy and safety of an Ayurveda intervention ( Materials and methods: This was an open-label randomized controlled pilot study with a sample size of 30 participants (15 in each arm). The participants were asymptomatic or mild to moderate cases of COVID-19. Results: The proportion of participants with negative RT-PCR for COVID-19 in the Conclusion: In this study on asymptomatic and mild to moderate cases of COVID-19,

Indexed as

Coronavirus disease-19GuduchiGuduchighana Vatisevere acute respiratory syndrome coronavirus 2Tinospora cordifolia

Identifiers

PMID35370379
PMCPMC8966758
OpenAlexW4213429575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.